

August 16, 2018



Arch Therapeutics Announces Poster Presentation at the 2018 Military Health System Research Symposium on Tuesday, August 21, 2018

Early stage ophthalmology and anti-inflammation pipeline projects highlighted

FRAMINGHAM, Mass., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of AC5™ Topical Gel ("AC5™"), today announced that new research involving AC5™ will be presented in a poster at the 2018 Military Health System Research Symposium (MHSRS) in Kissimmee, Florida. The MHSRS will take place from August 20-23, 2018 at the Gaylord Palms Resort and Convention Center.

The Arch poster "Anti-Inflammatory Effect of a Self-Assembling Peptide (AC5™) in the Lipopolysaccharide Induced Inflammation Model of Eye Injury", Ellis-Behnke et al., (poster #MHSRS-18-1422) will be included as part of the Vision Ocular Trauma Casualty Management Grand Rounds. Rutledge Ellis-Behnke, PhD, Arch co-founder and advisor, and principle investigator of the research, along with Terrence W. Norchi, MD and Arch CEO will present the poster from 10 AM to 12 PM ET on August 21, 2018. Registration for the Symposium can be found at the following link: <https://www.mhsrs.net>.

"We are pleased to present this important research, which highlights some exciting elements of our pipeline," said Dr. Norchi. "Our clinical and research programs continue to advance our self-assembling technology platform. We look forward to multiple milestones over the next several months, including the results of the sensitization study and anticipated regulatory filings for commercialization."

About Arch Therapeutics, Inc.

Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch's development stage product candidates include the AC5™ Topical Gel and the AC5™ Surgical Hemostatic Device.

About MHSRS

The MHSRS is the Department of Defense's premier scientific meeting. It provides a venue for presenting new scientific knowledge resulting from military-unique research and

development. The MHSRS is the only military or civilian meeting that focuses specifically on the unique medical needs of the Warfighter.

The MHSRS provides a collaborative setting for the exchange of information between military providers with deployment experience, research and academic scientists, international partners, and industry on research and related health care initiatives falling under the topic areas of Combat Casualty Care, Military Operational Medicine, Clinical and Rehabilitative Medicine, Medical Simulation and Information Sciences, and Military Infectious Disease.

Notice Regarding Forward-Looking Statements

This news release contains “forward-looking statements” as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to obtain required regulatory approvals, our ability to produce commercial quantities of our products within projected timeframes, our ability to develop and commercialize products based on our technology platform, and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.

Source: Arch Therapeutics, Inc.

Contact

ARTH Investor Relations

Toll Free: +1-855-340-ARTH (2784) (US and Canada)

Email: investors@archtherapeutics.com

Website: www.archtherapeutics.com

or

Richard Davis

Chief Financial Officer

Arch Therapeutics, Inc.

Phone: 617-431-2308

Email: rdavis@archtherapeutics.com

Website: www.archtherapeutics.com



Source: Arch Therapeutics, Inc.